{ "Long-Term Study of Ralinepag for Pulmonary Arterial Hypertension (PAH)", "This study is looking at the long-term effects of ralinepag in people who have pulmonary arterial hypertension (PAH), a type of high blood pressure in the lungs. It's an extension study for those who have already participated in an earlier study of ralinepag. The main goal is to see how safe ralinepag is over time by tracking any side effects you might experience for up to six years. To join, you must be at least 18 years old and have already been part of a previous ralinepag study for PAH. You'll continue to take ralinepag along with your current PAH medications. The study aims to enroll about 1000 participants. The current status of this study is unclear.", "design": "This is an open-label extension study, meaning you and your doctors will know you are receiving ralinepag. It is for participants who have already been in a Phase 2 or Phase 3 ralinepag study.", "commitments": "You will need to attend scheduled visits, follow the treatment plan, and complete laboratory tests and other study procedures for up to six years.", "compensation": "Not stated in the trial record.", "follow_up": "Your safety and side effects will be monitored for up to six years after starting the study.", }

Study design

Not specified.

What's involved

Not specified in the trial record.

Compensation

Not stated in the trial record.

Follow-up

Not specified.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.